First Patient Dosed in CatalYm’s Phase IIb Visugromab Trial

Why It Matters

Visugromab could address both immune resistance and cancer cachexia, two major hurdles in advanced HCC, potentially expanding therapeutic options and improving survival for a high‑need patient population.

Key Takeaways

• First patient dosed in CatalYm’s Phase IIb visugromab HCC trial
• Trial tests visugromab with nivolumab and lenvatinib in second‑line setting
• Targets GDF‑15 to overcome anti‑PD‑1 resistance and cachexia
• Enrolling 104 patients across 40 sites globally
• Primary endpoint: progression‑free survival; secondary includes overall survival

Pulse Analysis

Hepatocellular carcinoma remains the world’s third leading cause of cancer death, with most patients diagnosed at an advanced stage where curative surgery is impossible. First‑line regimens, typically atezolizumab‑bevacizumab or durvalumab‑tremelimumab, extend survival but resistance emerges quickly, leaving a narrow therapeutic window for second‑line options. Current agents such as regorafenib, cabozantinib, and ramucirumab provide modest benefits and do not address the profound muscle wasting—cachexia—that afflicts roughly 25% of HCC patients at diagnosis.

CatalYm’s visugromab targets growth differentiation factor‑15 (GDF‑15), a cytokine that suppresses anti‑tumor immunity and drives cachexia. By neutralising GDF‑15, the monoclonal antibody aims to restore sensitivity to PD‑1 blockade while simultaneously mitigating weight loss, a dual mechanism not seen in existing treatments. The Phase IIb GDFATHER‑HCC‑01 trial pairs visugromab with nivolumab and lenvatinib, leveraging the proven efficacy of the PD‑1 inhibitor and the multi‑kinase activity of lenvatinib. An initial open‑label safety run‑in will define the optimal dose before a double‑blind comparison against placebo plus lenvatinib, with progression‑free survival as the primary readout and overall survival, response rate, and cachexia metrics as secondary endpoints.

If successful, visugromab could reshape the HCC treatment paradigm by delivering a biologic that both re‑sensitises tumours to immunotherapy and improves patients’ functional status. Such an outcome would meet a critical unmet need, potentially extending median survival beyond the current 8‑12 months for second‑line therapy and reducing the burden of cachexia on quality of life. Investors are watching closely, as a positive readout could accelerate regulatory pathways and position CatalYm as a niche innovator in the competitive liver‑cancer market.